Human cerebral cortical polymicrogyria is a heterogeneous disorder, with only one known gene (GPR56) associated with an apparently distinctive phenotype, termed bilateral frontoparietal polymicrogyria (BFPP). To define the range of abnormalities that could be caused by human GPR56 mutations and to establish diagnostic criteria for BFPP, we analyzed the GPR56 gene in a cohort of 29 patients with typical BFPP. We identified homozygous GPR56 mutations in all 29 patients with typical BFPP. The total of 11 GPR56 mutations found represented a variety of distinct founder mutations in various populations throughout the world. In addition, we analyzed five patients with BFPP who did not show GPR56 mutation and found that they define a clinically, radiographically, and genetically distinct syndrome that we termed BFPP2. Finally, we studied seven patients with a variety of other polymicrogyria syndromes including bilateral frontal polymicrogyria, bilateral perisylvian polymicrogyria, and bilateral generalized polymicrogyria. No GPR56 mutation was found in these patients. This study provides a molecular confirmation of the BFPP phenotype and provides the wherewithal for diagnostic screening.
Polymicrogyria is a cortical malformation characterized by supernumerary, small gyri with abnormal cortical lamination. Harbord and colleagues 1 first described bilateral frontoparietal polymicrogyria (BFPP; OMIM 606854), an autosomal recessively inherited condition, as an "autosomal recessive neuronal migration defect with nonprogressive cerebellar ataxia." Since this initial description, many cases of BFPP have been reported under five different diagnoses: "autosomal recessive syndrome of pachygyria," "neuronal migration abnormality," "cobblestone lissencephaly," "lissencephaly with cerebellar hypoplasia," and "bilateral frontoparietal polymicrogyria." [1] [2] [3] [4] [5] [6] Using clinical and genetic approaches, we have defined the typical features of BFPP (see Discussion) and linked the BFPP locus to chromosome 16q12-21. 6, 7 Recently, mutations of the GPR56 gene were reported in patients with BFPP, mostly in patients originating from the Middle East, except for one founder mutation shared by three families from India, Pakistan, and Afghanistan and another mutation in a nonconsanguineous French Canadian family. 8 This study summarizes the previously identified BFPP families and describes additional mutational analysis in six new BFPP families with more diverse ethnic backgrounds and in patients with a variety of other bilateral polymicrogyria syndromes.
Subjects and Methods Patients
The newly identified BFPP families comprise four consanguineous families (Table 1 ; Pedigrees 14 -17) and two nonconsanguineous families (see Table 1 ; Pedigrees 13 and 18). Informed consent was obtained from all patients according A second group of patients also showed similar cortical malformation to that seen in patients with BFPP, but they lacked many of the typical features for BFPP associated with GPR56 mutations (Fig 1A) , so we refer to this syndrome as BFPP2. Specifically, Family A1 was a previously reported case. 9 It is a consanguineous family from the United Arab Emirates with one affected individual (see Table 1 ). The parents of Families A2 through A5 are nonconsanguineous (see Table 1 ). To determine the spectrum of malformation caused by GPR56 mutations, we also analyzed the GPR56 gene in several other polymicrogyria syndromes. These patients included two with bilateral frontal polymicrogyria, one with bilateral perisylvian polymicrogyria, and four with bilateral generalized polymicrogyria (see Table 1 and Fig 1B) .
Mutation Analysis
DNA was extracted from peripheral blood with the use of standard methods. The GPR56 gene spans 45kb at the genomic level and is composed of 14 exons with a coding region of 2,061bp (GenBank accession number AF106858) from exons 2 to 14 (Fig 2) . Primer pairs for amplification of each of the 13 GPR56 coding exons (exons 2-14) were generated from the genomic sequence of GPR56 (University of California, Santa Cruz, Genome Bioinformatics, Santa Cruz, CA; GPR56 [Homo sapiens] range ϭ chr16: 56211459 -56256445). Exons were sequenced directly by BigDye Terminator sequencing (Applied Biosystems, Foster City, CA). Primer sequences are listed in Table 2 .
Results
Sequence alterations in GPR56 were found in all 29 patients with typical BFPP. Combined with the previous study, a total of 11 different mutations were identified, including 8 missense mutations, 2 splicing mutations, and 1 deletion mutation resulting in a translational frameshift and premature protein termination (Table 3 ; see Fig 2) . All mutations except one missense mutation shared an indistinguishable phenotype, suggesting all are probably null alleles. The C346S mutation found in Families 8 and 9 also causes microcephaly, presumably by affecting proper protein trafficking of GPR56 and possibly that of other proteins (Table 3) . 6 In each pedigree analyzed, the GPR56 mutation always segregated with the disease in the respective families and was not seen in 260 chromosomes from control subjects (70 Europeans and 60 Middle Eastern Arabian individuals). All patients, including those from nonconsanguineous families, carried homozygous mutations. Interestingly, all missense mutations affect regions of the protein predicted to represent the extracellular part of GPR56 (see Fig 2) .
No GPR56 mutations were found in 12 patients with a variety of other polymicrogyria syndromes (see Table 1 ). For example, although the cortical malformation in patients with BFPP2 (Families A1-A5) resembles BFPP (ie, bilateral polymicrogyria that is worst in the frontal and parietal regions with an anterior-toposterior gradient), these pedigrees showed fewer of the diagnostic criteria for typical BFPP, and none of them harbored a mutation in the GPR56 gene (see Table 4 ). Interestingly, none of them had both white matter abnormalities and hypoplasia of the pons or cerebellar vermis. We thus suggest use of the term BFPP2 to re- fer to patients with BFPP, but who lack some of the diagnostic criteria for typical BFPP, show no mutation in GPR56, or both. However, patients with BFPP2 were not phenotypically homogeneous, which suggests that they are unlikely to represent a single clinical group. Although our coding sequence analysis alone cannot exclude regulatory mutations, the combination of genetic analyses and careful review of brain magnetic resonance images lend further support for a demarcation between classic BFPP and BFPP2. In addition, we performed linkage analysis on Family A1, the only consanguineous family from this group, and found no evidence for linkage to the GPR56 locus (data not shown). Therefore, we conclude that there is a clear genetic separation between patients with classic BFPP and those with BFPP2. Furthermore, no mutation in GPR56 was found in any of the patients with bilateral frontal polymicrogyria, bilateral perisylvian polymicrogyria, and bilateral generalized polymicrogyria, suggesting the phenotype of GPR56 mutation does not extend to other types of bilateral polymicrogyria syndromes.
Discussion
Here, we presented clinical phenotype of 29 BFPP patients harboring mutations in GPR56 who share considerable clinical homogeneity with 5 common clinical features and 3 typical magnetic resonance imaging findings identified: (1) mental retardation of moderate to severe degree; (2) motor developmental delay; (3) seizures, most commonly symptomatic generalized epilepsy; (4) cerebellar signs, consisting of ataxia; (5) dysconjugate gaze, presenting variably as esotropia, nystagmus, exotropia, or strabismus; (6) bilateral polymicrogyria with anterior to posterior gradient; (7) bilateral patchy white matter signal changes without specific pattern; and (8) brainstem and cerebellar hypoplasia (see Fig 1A) . Mental retardation and motor developmental delay were documented in all patients who had complete medical records available for review, whereas cerebellar signs, dysconjugate gaze, and seizures were presented in 94, 88, and 95% of BFPP cases, respectively (see Table 4 ).
The families analyzed here are from different ethnic groups with a wide geographic distribution, including Arabic-speaking Middle Eastern, Pakistani, Indian, Afghani, Canadian, Turkish, Italian, Israeli, and Hispanic American families. However, clinically, they have a homogeneous disease with typical clinical and radiographic features. The identification of mutations in GPR56 in an ethnically diverse group of patients demonstrates the extensive geographic distribution of BFPP. 2  TCCACACTTGCTTCCCCAC  TGCCAGAAGGAAGGAGTG  3  TAGGTCCTGTCCCCTTCCAT  CCCAGTCCACTTTGCATTTT  4  GTCATGTCAGGGTGGTAGGG  CCCCAGGTGCCAAACTTAC  5  CACCATCACCACCGCTTTC  GCGACGGCACTGAGCTTCAG  6  GGATGGGTGTGTGTGTGTGT  TGCCTTCTTTCCACCTCTGT  7  TGTGCTGGGAGAGGGTTATC  GAGTCTGGAGGGAGGGAGAG  8  TCTGCCTGGCCTGTAAAGTT  GCCATCGCTCTCTCTTCAAA  9  CTTTTGGGGGTGGACACAGT  ATGAAAAGTGCTTGCACAGA  10  ACCAGGGACCCCAGGTTAG  CCATGACCGGAGATGTGTG  11  AGGATAGGGGCCATGTATGA  TAGGTGGAGAGGCAGAACCA  12  GTCCAAACTTGGGGGAACTT  GGAGACTGGAACCCAGGTGT  13  CAAGCGCACTTGCTGTAAAC  AGGTTCCCTGGGTGATCTCT  14 CAGACCCGAGTCACAATGG GTTGGGCTTTCCAAAGTCTG GPR56 encodes a member of the Family B G protein-coupled receptors, which have long N termini characterized by an extracellular "cysteine box" and hydrophilic, potentially mucin-rich domains. 10 -12 The cysteine box contains four conserved cysteines and two tryptophans arranged in a specific fashion (C-x 2 -W-x 6-16 -W-x 4 -C-x 10-22 -C-x-C) just before the first transmembrane domain and serves as a cleavage site in some members of this group of G proteincoupled receptors. 13 Therefore, the cysteine box was also named the G protein-coupled receptor proteolytic site (GPS) domain. We have shown previously that substitution of one of the four conserved cysteines in GPS domain, C346S, also causes microcephaly. 8 Here, we show one new mutation in GPR56 that occurs in the GPS domain, which results in the substitution of one of the two conserved tryptophans for serine (W349S) in two Israeli Jewish families. The affected individuals, however, have normal head circumference. Further biochemical analysis of these two mutations may shed light on the function of the GPS domain in this subclass of G protein-coupled receptors.
Mutation W349S was shared by two Israeli Jewish families with no known relationship, but who also shared alleles at flanking single-nucleotide polymorphisms, suggesting that the mutation represents a founder mutation. Pedigree 14 is a Karaite family with consanguineous parents who reside in Israel. The parents in Pedigree 13 are nonconsanguineous, with both parents sharing Karaite ancestry. Karaites represent a small Jewish minority who follows tenets of the original form of Judaism.
Mutation R565W occurs in an Italian family (Pedigree 15) and was seen previously in Pedigree 10, an extended Bedouin family. 8 However, singlenucleotide polymorphism analysis suggested this was a coincidental mutation in two different families without evidence of common haplotype. This mutation is a C3 T transition at a CpG dinucleotide position. CpG dinucleotides mutate approximately 10 times faster than other dinucleotides due to cytosine methylation and the subsequent deamination and conversion of C3 T, which may explain this recurrent mutation.
14 In summary, BFPP is an autosomal recessive polymicrogyria syndrome, which was frequently misdiagnosed before the availability of genetic testing and high-resolution neuroimaging. Here, we have presented molecular analysis in a cohort of 29 classic BFPP patients from 18 ethnically diverse families and 12 patients with a variety of other polymicrogyria syndromes. We demonstrated that all predicted pathogenic GPR56 sequence alterations were only found in patients with typical BFPP. GPR56 mutations do not extend to cases of bilateral polymicrogyria that do not adhere to the BFPP cortical distribution, nor to cases with only the cortical abnormality but without both white matter and posterior fossa changes, and so we suggest the term BFPP2 to refer to these patients. This study has validated the precise criteria necessary for the accurate diagnosis of BFPP and provides a basis for genetic screening as part of a diagnostic workup. 
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